Cyclacel Pharmaceuticals (NASDAQ:BGMS) Issues Earnings Results

Cyclacel Pharmaceuticals (NASDAQ:BGMS) announced its quarterly earnings results on Friday. The company reported ($0.08) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.34 million during the quarter.

Cyclacel Pharmaceuticals Stock Down 1.1%

NASDAQ BGMS traded down $0.01 on Friday, reaching $0.92. The stock had a trading volume of 4,371 shares, compared to its average volume of 988,142. The stock has a fifty day moving average price of $0.89 and a two-hundred day moving average price of $0.97. Cyclacel Pharmaceuticals has a 12-month low of $0.57 and a 12-month high of $9.40. The firm has a market capitalization of $5.05 million, a price-to-earnings ratio of -0.20 and a beta of -0.38.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Cyclacel Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.